These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 1726006)

  • 1. Safety profile of lacidipine: a review of clinical data.
    Endersby CA; Brown EG; Perelman MS
    J Cardiovasc Pharmacol; 1991; 17 Suppl 4():S45-7. PubMed ID: 1726006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of lacidipine, a novel dihydropyridine calcium antagonist, on carbohydrate and lipid metabolism.
    Spieker C; Zidek W
    J Cardiovasc Pharmacol; 1995; 25 Suppl 3():S23-6. PubMed ID: 8852541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of lacidipine, a new long-lasting calcium antagonist, in elderly hypertensive patients.
    Rizzini P; Castello C; Salvi S; Recchia G
    J Cardiovasc Pharmacol; 1991; 17 Suppl 4():S38-43; discussion S43-4. PubMed ID: 1726005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A long-term study comparing lacidipine and nifedipine SR in hypertensive patients: safety data.
    Leonetti G; Salvi S
    J Cardiovasc Pharmacol; 1994; 23 Suppl 5():S108-10. PubMed ID: 7609496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. French large-scale study evaluating the tolerability and efficacy of lacidipine.
    Tcherdakoff P
    J Cardiovasc Pharmacol; 1995; 25 Suppl 3():S27-32. PubMed ID: 8852542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical evaluation of the efficacy and safety of manidipine in hypertensive patients with renal disorders.
    Mizuno K; Haga H; Takahashi M; Watanabe Y; Fukuchi S
    Blood Press Suppl; 1992; 3():119-23. PubMed ID: 1343279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lercanidipine in the treatment of hypertension.
    Beckey C; Lundy A; Lutfi N
    Ann Pharmacother; 2007 Mar; 41(3):465-73. PubMed ID: 17341540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selection of initial and maintenance dosages for lacidipine, a new once-daily calcium antagonist for the treatment of hypertension.
    Perelman M
    J Cardiovasc Pharmacol; 1991; 17 Suppl 4():S14-8; discussion S18-9. PubMed ID: 1726000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lacidipine: a review of its use in the management of hypertension.
    McCormack PL; Wagstaff AJ
    Drugs; 2003; 63(21):2327-56. PubMed ID: 14524737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calcium antagonist antihypertensive treatment of non-insulin-dependent diabetics: efficacy and safety of lacidipine versus nifedipine SR.
    Gulizia M; Valenti R; Platania F; D'Onofrio V; Rizzini P; Circo A
    J Cardiovasc Pharmacol; 1994; 23 Suppl 5():S101-4. PubMed ID: 7609494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The potential role of calcium antagonists in the management of congestive heart failure: initial experience with lacidipine.
    de Vries RJ; Dunselman PH
    J Cardiovasc Pharmacol; 1995; 25 Suppl 3():S33-9. PubMed ID: 8852543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative study of lacidipine and nifedipine SR in the treatment of hypertension: an Italian multicenter study. The Northern Italian Study Group of Lacidipine in Hypertension.
    Leonetti G
    J Cardiovasc Pharmacol; 1991; 17 Suppl 4():S31-4. PubMed ID: 1726003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular advantages of a third generation calcium antagonist. Symposium on lacidipine. Foreword.
    Zanchetti A
    Drugs; 1999; 57 Suppl 1():2 p preceding 1. PubMed ID: 10529077
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical position of lacidipine, a new dihydropyridine calcium antagonist, in the treatment of hypertension.
    Leonetti G
    J Cardiovasc Pharmacol; 1991; 18 Suppl 11():S18-21. PubMed ID: 1725445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lacidipine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of hypertension.
    Lee CR; Bryson HM
    Drugs; 1994 Aug; 48(2):274-96. PubMed ID: 7527328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lercanidipine in hypertension.
    Borghi C
    Vasc Health Risk Manag; 2005; 1(3):173-82. PubMed ID: 17319103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolerability of high doses of lercanidipine versus high doses of other dihydropyridines in daily clinical practice: the TOLERANCE Study.
    Barrios V; Escobar C; de la Figuera M; Llisterri JL; Honorato J; Segura J; Calderón A
    Cardiovasc Ther; 2008; 26(1):2-9. PubMed ID: 18466416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lercanidipine vs lacidipine in isolated systolic hypertension.
    Millar-Craig M; Shaffu B; Greenough A; Mitchell L; McDonald C
    J Hum Hypertens; 2003 Nov; 17(11):799-806. PubMed ID: 14578921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety aspects of treatment with lacidipine--a slow-onset, long-acting calcium antagonist.
    Lindholm LH; Tcherdakoff P; Zanchetti A
    Blood Press; 1996 Jul; 5(4):241-9. PubMed ID: 8809376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of lacidipine, a dihydropyridine calcium antagonist on renal function of hypertensive patients with renal insufficiency.
    Bailey RR; Shand BI; Smith AH; Robson RA; Lynn KL
    Clin Nephrol; 1997 Oct; 48(4):224-9. PubMed ID: 9352156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.